Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 180

1.

Modulation by miR-29b of intestinal epithelium homoeostasis through the repression of menin translation.

Ouyang M, Su W, Xiao L, Rao JN, Jiang L, Li Y, Turner DJ, Gorospe M, Wang JY.

Biochem J. 2015 Jan 15;465(2):315-23. doi: 10.1042/BJ20141028.

2.

miR-24 regulates menin in the endocrine pancreas.

Vijayaraghavan J, Maggi EC, Crabtree JS.

Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E84-92. doi: 10.1152/ajpendo.00542.2013. Epub 2014 May 13.

3.

The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit".

Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi ML.

PLoS One. 2012;7(6):e39767. doi: 10.1371/journal.pone.0039767. Epub 2012 Jun 27.

4.

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML; Endocrine Society.

J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011. doi: 10.1210/jc.2012-1230. Epub 2012 Jun 20. Review.

PMID:
22723327
5.
6.

The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases.

Luzi E, Marini F, Tognarini I, Galli G, Falchetti A, Brandi ML.

Nucleic Acid Ther. 2012 Apr;22(2):103-8. doi: 10.1089/nat.2012.0344. Epub 2012 Mar 12.

PMID:
22409234
7.

Parathyroid carcinoma in multiple endocrine neoplasia type 1. Case report and review of the literature.

del Pozo C, García-Pascual L, Balsells M, Barahona MJ, Veloso E, González C, Anglada-Barceló J.

Hormones (Athens). 2011 Oct-Dec;10(4):326-31. Review.

8.

Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.

Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, Young J, Delemer B, Du Boullay H, Verger MF, Kuhn JM, Sadoul JL, Ruszniewski P, Beckers A, Monsaingeon M, Baudin E, Goudet P, Tabarin A.

Eur J Endocrinol. 2012 Feb;166(2):269-79. doi: 10.1530/EJE-11-0679. Epub 2011 Nov 14.

9.

Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database.

Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, Imai T, Kaji H, Komoto I, Miura D, Yamada M, Uruno T, Horiuchi K, Miyauchi A, Imamura M; MEN Consortium of Japan, Fukushima T, Hanazaki K, Hirakawa S, Igarashi T, Iwatani T, Kammori M, Katabami T, Katai M, Kikumori T, Kiribayashi K, Koizumi S, Midorikawa S, Miyabe R, Munekage T, Ozawa A, Shimizu K, Sugitani I, Takeyama H, Yamazaki M.

Clin Endocrinol (Oxf). 2012 Apr;76(4):533-9. doi: 10.1111/j.1365-2265.2011.04227.x.

PMID:
21950691
10.

Glucagonoma syndrome: a case report.

Castro PG, de León AM, Trancón JG, Martínez PA, Alvarez Pérez JA, Fernández Fernández JC, García Bernardo CM, Serra LB, González González JJ.

J Med Case Rep. 2011 Aug 22;5:402. doi: 10.1186/1752-1947-5-402.

11.

Are microRNAs involved in the endocrine-specific pattern of tumorigenesis in multiple endocrine neoplasia type 1?

Luzi E, Brandi ML.

Endocr Pract. 2011 Jul-Aug;17 Suppl 3:58-63. doi: 10.4158/EP11062.RA. Review.

PMID:
21613051
12.

Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.

Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, Awane M, Inoue N.

World J Gastroenterol. 2011 Mar 14;17(10):1343-53. doi: 10.3748/wjg.v17.i10.1343.

13.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

14.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.

N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. Erratum in: N Engl J Med. 2011 Mar 17;364(11):1082.

15.

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism.

Moyes VJ, Monson JP, Chew SL, Akker SA.

Int J Endocrinol. 2010;2010:906163. doi: 10.1155/2010/906163. Epub 2010 May 26.

16.

Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.

Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C.

World J Surg. 2010 Feb;34(2):249-55. doi: 10.1007/s00268-009-0290-1.

PMID:
19949948
17.

How should the patient with multiple endocrine neoplasia type 1 (MEN 1) be followed?

Burgess J.

Clin Endocrinol (Oxf). 2010 Jan;72(1):13-6. doi: 10.1111/j.1365-2265.2009.03662.x. Epub 2009 Jun 22. Review.

PMID:
19552677
18.

Familial pituitary adenomas.

Tichomirowa MA, Daly AF, Beckers A.

J Intern Med. 2009 Jul;266(1):5-18. doi: 10.1111/j.1365-2796.2009.02109.x. Review.

19.

Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation.

Shih RY, Fackler S, Maturo S, True MW, Brennan J, Wells D.

Endocr Pract. 2009 Sep-Oct;15(6):567-72. doi: 10.4158/EP09045.CRR1.

PMID:
19491073
20.

Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.

Vierimaa O, Villablanca A, Alimov A, Georgitsi M, Raitila A, Vahteristo P, Larsson C, Ruokonen A, Eloranta E, Ebeling TM, Ignatius J, Aaltonen LA, Leisti J, Salmela PI.

J Endocrinol Invest. 2009 Jun;32(6):512-8. doi: 10.3275/6107. Epub 2009 Mar 26.

PMID:
19474519

Supplemental Content

Support Center